Skip to main content

Thank you Jordan! You raise a very important point- I definitely think the next step in AML research is to focus on developing effective biomarkers to determine the resistance and relapse of these novel therapeutics. Researching this at the "bench-side" will help to further enhance patient care on the "bed-side"- gracefully depicting the essence of translational medicine.

Name
Melinda Chelva

Plain text

  • No HTML tags allowed.
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.